LT-NS001, A NAPROXEN PRO-DRUG WITH MINIMAL COX INHIBITION WHILE INTACT, RESULTS IN EQUAL PLASMA EXPOSURE TO NAPROXEN IN VOLUNTEERS AGED 45-70 COMPARED WITH NAPROSYN®.

(1) Gastroenterology, University of Illinois at Chicago, Chicago IL

(2) Pharmacokinetics, Kramer Consulting, Inc., No. Potomac MD

(3) Medicine, Dedicated Phase 1, Inc., Phoenix AZ, United States

(4) Medicine, Charles Univ./South Bohemia Univ.

(5) Medicine, Quinta, Prague

(6) Medicine, CEPHA, Pilsen, Czech Republic

(7) Medicine, CEDRA, Austin TX

(8) Clin. Dev., Logical Therapeutics, Inc., Waltham MA, United States



This item was part of the OESOPHAGEAL, GASTRIC AND DUODENAL DISORDERS II session at Gastro 2009 UEGW/WCOG London (17th UEGW)